Black Diamond lays off 30% of its workforce and culls a drug from its 'MasterKey' chest

Kyle LaHucik

Senior Reporter

With every round of layoffs, the doldrums of the biotech bear market get ever darker and more depressing. Black Diamond Therapeutics is the latest to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Black Diamond lays off 30% of its workforce and culls a drug from its 'MasterKey' chest

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Novo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion

A startup backed by Nobel winner David Baker takes an AI twist on antibodies

#HLTH24: GLP-1 compounding pharmacies took center stage at digital health’s biggest conference

BeiGene executive reportedly under investigation in China

AstraZeneca China exec probed by local authorities

Black Di­a­mond lays off 30% of its work­force and culls a drug from its 'Mas­terKey' chest

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Black Diamond lays off 30% of its workforce and culls a drug from its 'MasterKey' chest